Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

nilotinib 12Imatinib Mesylate 11Dasatinib 3ruxolitinib 2posaconazole 2fludarabine 2bosutinib 2asciminib 2Cyclophosphamide 2Busulfan 2zanubrutinib 1trametinib 1pegaspargase 1flumatinib 1fludarabine phosphate 1eltrombopag 1dabrafenib 1avapritinib 1Thiotepa 1Rituximab 1Radiotherapy 1Phlebotomy 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Micafungin 1Interferons 1Idarubicin 1Hydroxyurea 1Growth Hormone 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Interferons × Myeloid × Clear all
NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

PETHEMA Foundation

Phase 4 Completed
360 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡